New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

• Open-label,single-arm, phase 2 study

Pretreated metastatic or recurrent ACC

Axitinib + Avelumab q28 (n=28)

ORR: 21% [8.3%-41.0%]

mPFS: 7.3 mos [3.7-11.2 mos]

mOS: 1.6 mos [12.4-NR]

Any grade AEs: fatigue (62%), diarrhea (32%), hypertension (32%), mucositis (29%)

Grade3 AEs: hypertension (9%), fatigue (6%), palmar-plantar erythrodysesthesia (6%)

Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023